Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
about
The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesSelective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.Breastfeeding and chronic HBV infection: clinical and social implicationsClinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography.Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy.Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.Pharmacokinetics and tissue distribution of 14C-labeled grape polyphenols in the periphery and the central nervous system following oral administration.
P2860
Q25257032-00829BA5-6834-4721-8AE0-AAF83022E9C4Q28775900-CF4E8B19-9D98-4AE9-BCC6-FD4DB3B71055Q33769993-D019ECA7-510B-46A8-9D7F-D4196B93E23DQ33770127-7CDBA737-A920-4A16-BBE8-576F4B77E594Q33805141-9B4A03A8-418D-4BB1-ABDE-9C1B09384B72Q34246938-5464A945-AE27-4674-AA3A-4CD122F6F16DQ35558801-EC88AAC5-8E13-4A68-8433-1D051726BC9CQ36558253-930DD9ED-7B00-4C8B-B307-4C07F41518E3Q36870864-600D3E0D-1EDF-4550-A447-9EDA409AA86DQ37392720-9C455735-7281-473D-986A-F848B0495BC4Q39791215-9F895302-1CF2-48AC-89FD-9932666F92F7Q40100382-D860B82D-8D63-4AE9-A17B-178D5C812744Q42792616-6A160B6A-ABE9-48D8-816D-4C491725E581
P2860
Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Pharmacokinetics and bioavaila ...... propyl]adenine (PMPA) in dogs.
@ast
Pharmacokinetics and bioavaila ...... propyl]adenine (PMPA) in dogs.
@en
type
label
Pharmacokinetics and bioavaila ...... propyl]adenine (PMPA) in dogs.
@ast
Pharmacokinetics and bioavaila ...... propyl]adenine (PMPA) in dogs.
@en
prefLabel
Pharmacokinetics and bioavaila ...... propyl]adenine (PMPA) in dogs.
@ast
Pharmacokinetics and bioavaila ...... propyl]adenine (PMPA) in dogs.
@en
P2093
P2860
P356
P1476
Pharmacokinetics and bioavaila ...... )propyl]adenine (PMPA) in dogs
@en
P2093
P2860
P304
P356
10.1128/AAC.42.3.687
P407
P577
1998-03-01T00:00:00Z